Established in 2005, Avivia is an independent Dutch company engaged in drug repositioning, repurposing and (re)formulation. Its expertise and capabilities are centred around developing value-added generic drugs, the life-cycle management of branded medicinal products, and complex formulations for generics and R&D activities related to new chemical entities (NCEs). Since its launch nearly 15 years ago, the company has built up a solid reputation, gaining recognition for its 'can-do' attitude to R&D and its practical flexibility and ‘inside-the-box’ creativity in addressing complex and challenging analytical and pharmaceutical development projects. Avivia is a preferred specialist partner of many big pharma, specialty pharma and generic drug companies and smaller drug development companies. Avivia operates a hybrid business model combining contract research organisation (CRO) service activities with proprietary internal product development programmes in the field of neglected tropical skin diseases (skin NTDs), novel antimicrobial peptides and heat-stable oxytocin formulation. Avivia’s offices and state-of-the-art lab facilities are located in Nijmegen in the Netherlands, close to the German and Belgian borders.
Partners
Avivia nv, The Netherlands
Team members
Johannes Platteeuw is Avivia’s Founder and CEO. He holds a master’s degree in chemistry from the University of Nijmegen in the Netherlands. He started his career at Synthon, managing pharmaceutical product development projects and went on to become the company’s Head of Galenical R&D, helping to improve the organisation of Synthon’s R&D and develop its product portfolio, including the granting of 10 worldwide patents. In 2004, he moved to Dafra Pharma, a private company specialising in antimalarial medication, where he served as Director of R&D and was instrumental in launching Co-Arinate, which provided effective malarial treatment within 24 hours that cured already over 15 million patients in Africa. In 2005, he set up Avivia as an independent company specialising in developing and protecting the intellectual property associated with generic specialty pharmaceuticals. Through Avivia he has served as a Project Manager for numerous companies (Disphar, Organon/SP, Pharming, Virostatics, Genetic Immunity, Metaptys), as Chief Operating Officer (Formac Pharmaceuticals), Chief Development Officer (Chamaeleo) and as a Director of Pharmaceutical R&D (Pantarhei). His work for most of these companies resulted in further patent applications (15) and licensing deals and generated significant revenue.
He will oversee the CMC studies.
Menno Wiltink is a Partner at Avivia with 25 years' experience in pharmaceutical R&D and expertise in analytical research and support, API, excipient and drug product characterisation and troubleshooting, predictive dissolution testing, preclinical evaluation and equivalence selection. He was Head of Analytical Development at Synthon and studied Analytical Sciences at the University of Amsterdam and Environmental Analysis at the Van Hall Larenstein University of Applied Sciences in Leeuwarden.
He will be a Project Leader for CMC work.
Hans van der Steen gained a bachelor's degree in analytical chemistry from Fontys University of Applied Sciences in Eindhoven and went on to obtain more than 10 years' experience in analytical chemistry in the pharmaceutical and excipient industry at Organon, CP Kelco and Synthon Biopharmaceuticals. He joined Avivia in 2015. His field of interest and area of expertise include active pharmaceutical ingredients (API) and excipient characterisation, analytical research and support, and drug product troubleshooting and development.
Apart from acting as a Project Leader for CMC, he will be responsible for managing the practical work in Avivia's analytical lab.
Dennie van den Heuvel is a Partner at Avivia with over 20 years' experience in the pharmaceutical industry. He is also an expert on formulation development and related topics from pre-clinical development to production, intellectual property and regulatory requirements. He previously served in various capacities at Intervet/AkzoNobel and Synthon and is a seasoned project manager, working in and leading or coaching interdisciplinary teams (chemistry, manufacturing and controls (CMC), toxicology, clinical and regulatory aspects and analytics). He invented more than 25 patents for Synthon.
He will provide additional oversight for the CMC studies.
Marleen De Vriese gained a master's degree in Biomedical Sciences from the University of Antwerp in Belgium and has since racked up over 15 years' experience in managing pharmaceutical development projects at Dafra Pharma (in R&D), Formac and Avivia. Her focus at Avivia is on the daily follow-up on in-house development programmes.
She will also do the daily follow-up management of the project within Avivia.
Rianne Visser holds a master’s degree in Molecular Life Sciences from Radboud University in Nijmegen. At Avivia, she assists the Analytical and Pharmaceutical R&D team, primarily providing research and support services and doing practical work in our pharmaceutical and analytical lab.
She will also assist the project of TT4CL (CMC).
